Piper Sandler cautiously optimistic about Coinbase (COIN) despite staking concerns
Get Alerts COIN Hot Sheet
Rating Summary:
22 Buy, 16 Hold, 6 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
PiperSandler analyst Richard Repetto maintained an Overweight rating and $65 per share price target on Coinbase (NASDAQ: COIN) Monday but said the firm is cautious on regulatory risk as the SEC eyes staking.
Last week the SEC announced charges against cryptocurrency exchange Kraken, alleging its crypto staking-as-a-service program amounted to offering unregistered securities products in the US.
To settle the charges, Kraken agreed to pay $30 million and shut all of its US staking services, sparking concerns about a broader crackdown on cryptocurrency staking.
Repetto said in his note that the following day, SEC Chair Gary Gensler appeared on both CNBC & Bloomberg TV and was critical of intermediary
crypto storefronts offering staking products similar to Kraken's, urging them to "come in to compliance."
However, on Friday, Coinbase Chief Legal Officer Paul Grewal argued that the company's staking offering differs from Kraken's and is not a security under the US Securities Act or the "Howey test."
As a result, Repetto told investors that the firm is cautiously optimistic as Coinbase could undergo a key test of regulatory compliance.
"COIN has long touted the regulatory compliance of its crypto products & services, platform, and general operations," the analyst wrote. "As the SEC moves toward what appears to be a more aggressive stance on crypto regulation, we are cautiously optimistic that COIN won't be weighed down by recently increased scrutiny around staking."
He acknowledged that while the recent pullback in the stock clearly reflects the possibility of increased regulatory risk, Piper Sandler still believes longer-term regulatory clarity is "likely positive both for the crypto industry and COIN itself."
By Sam Boughedda
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mirum and Incyte report positive phase 2 results for FOP treatment
- FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
- IQM names Barbara Venneman to board ahead of planned Nasdaq listing
Create E-mail Alert Related Categories
Analyst Comments, Cryptocurrency, Hot ListSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share